secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0001437749-25-002265
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene enters subaward amendment for up to $8M from NIH for ALS Expanded Access Program
--------------------------------------------------------------------------------

- Amendment with Columbia University on Jan 28, 2025, extends funding for Year 2 of ACT-EAP from Sep 1, 2024 to Aug 31, 2025.
- Additional $7,976,230 obligated; cumulative funding to date totals $15,324,600.
- Supports CNM-Au8 treatment in ALS under the Accelerating Access to Critical Therapies for ALS Act.
- Other Subaward terms from April 2024 remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925002265/0001437749-25-002265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925002265/clnn20241218_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-002265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer